UY35465A - Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) - Google Patents
Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)Info
- Publication number
- UY35465A UY35465A UY0001035465A UY35465A UY35465A UY 35465 A UY35465 A UY 35465A UY 0001035465 A UY0001035465 A UY 0001035465A UY 35465 A UY35465 A UY 35465A UY 35465 A UY35465 A UY 35465A
- Authority
- UY
- Uruguay
- Prior art keywords
- ret
- reorganized
- new compounds
- during transfection
- inhibitors during
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000001890 transfection Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072683 | 2013-03-15 | ||
| CN2013090059 | 2013-12-20 | ||
| CN2014072449 | 2014-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35465A true UY35465A (es) | 2014-10-31 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035465A UY35465A (es) | 2013-03-15 | 2014-03-14 | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
Country Status (33)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
| EP3191480A1 (en) * | 2014-09-08 | 2017-07-19 | GlaxoSmithKline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| CA2960768A1 (en) * | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
| WO2016037578A1 (en) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX384884B (es) | 2015-11-02 | 2025-03-14 | Blueprint Medicines Corp | Inhibidores de ret. |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| AU2017263174A1 (en) | 2016-05-13 | 2018-12-13 | Instituto de Medicina Molecular João Lobo Antunes | Methods of treating diseases associated with ILC3 cells |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110891573A (zh) | 2017-05-15 | 2020-03-17 | 缆图药品公司 | Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途 |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3773589B1 (en) | 2018-04-03 | 2023-11-01 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| JP7461605B2 (ja) * | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
| AR121914A1 (es) | 2020-04-27 | 2022-07-20 | Lilly Co Eli | Compuestos útiles para inhibir la quinasa ret |
| KR20230017234A (ko) | 2020-05-29 | 2023-02-03 | 블루프린트 메디신즈 코포레이션 | 프랄세티닙의 고체 형태 |
| WO2022017524A1 (zh) * | 2020-07-23 | 2022-01-27 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| US11697647B2 (en) | 2020-11-06 | 2023-07-11 | Eli Lilly And Company | RET kinase inhibitors |
| WO2022254255A1 (en) | 2021-06-03 | 2022-12-08 | Fundacao D. Anna De Sommerchampalimaud E Dr. | Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| EP4650002A1 (en) * | 2024-05-15 | 2025-11-19 | Ludwig-Maximilians-Universität | Aniline-based modulators of the nuclear receptor tlx (nr2e1) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL353455A1 (en) | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| CA2430151A1 (en) * | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| RU2009118254A (ru) | 2006-10-16 | 2010-11-27 | Новартис АГ (CH) | Фенилацетамиды в качестве ингибиторов протеинкиназ |
| HUE035868T2 (en) * | 2006-11-15 | 2018-05-28 | Ym Biosciences Australia Pty | Inhibitors of kinase activity |
| JP2013502429A (ja) * | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
-
2014
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 SM SM20170152T patent/SMT201700152T1/it unknown
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en not_active Ceased
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35465A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| CR20170093A (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfección) | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
| MX2020001360A (es) | Macrociclos de diarilo como moduladores de la proteina quinasa. | |
| DOP2017000035A (es) | Inhibidores de la proteina quinasa c y metodos de su uso | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| MX2019009695A (es) | Inhibidores espirociclicos de catepsina c. | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| CR20140512A (es) | Dispositivos y metodos para la fabricación de aditivos de componentes de implante | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| GT201200147A (es) | Antagonistas de espiro-oxindol de mdm2 | |
| MX381235B (es) | Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CY1122763T1 (el) | Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona |